Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer

被引:0
|
作者
Kumiko Hongo
Shinsuke Kazama
Eiji Sunami
Nelson H. Tsuno
Koki Takahashi
Hirokazu Nagawa
Joji Kitayama
机构
[1] The University of Tokyo,Department of Surgical Oncology, Faculty of Medicine
[2] The University of Tokyo,Department of Transfusion Medicine, Faculty of Medicine
[3] Japan Labour,undefined
[4] Health and Welfare Organization,undefined
来源
Medical Oncology | 2012年 / 29卷
关键词
CD133; Colorectal cancer; Chemoradiotherapy; Immunohistochemical detection;
D O I
暂无
中图分类号
学科分类号
摘要
CD133 has been identified as a putative cancer stem cell (CSC) marker in various cancers including colorectal cancer. The relation between CD133 expression and biological characteristics of colorectal cancer remains to be clarified. Protein expression of CD133 was immunohistochemically evaluated in surgical specimens of 225 patients with colorectal cancer who were treated by surgery, as well as those of 78 patients with rectal cancer who received preoperative chemoradiotherapy (CRT) followed by curative resection. The correlation between CD133 expression and clinicopathological features, tumor recurrence and overall survival was analyzed in both populations. Among 225 colorectal cancers without CRT, 93 (41.3%) were positive for CD133 expression, which was enhanced in cases with advanced T stage and venous invasion. Moreover, CD133 was positive in 47 (60.3%) of 78 cases with CRT, which was significantly higher than the CD133-positive rate in non-CRT specimens (P = 0.05). Expression of CD133 was independently correlated with the histological tumor regression grade (P < 0.01). These results suggest that CD133 is not a distinctive colorectal CSC marker; expression of CD133 is suggested to be one of the key factors associated with resistance to CRT in colorectal cancer.
引用
收藏
页码:2849 / 2857
页数:8
相关论文
共 50 条
  • [31] Immunohistochemical Detection of Cancer Stem Cell Related Markers CD44 and CD133 in Metastatic Colorectal Cancer Patients
    Pitule, Pavel
    Cedikova, Miroslava
    Daum, Ondrej
    Vojtisek, Jan
    Vycital, Ondrej
    Hosek, Petr
    Treska, Vladislav
    Hes, Ondrej
    Kralickova, Milena
    Liska, Vaclav
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [32] Importance of Tumor Regression Grade in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy
    Chung, J. H.
    Song, C.
    Kang, S. B.
    Kim, D. W.
    Kim, J. H.
    Lee, K. W.
    Kim, J. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E3 - E3
  • [33] Tumor Regression Grade and Rectal Cancer Reply
    Brown, Gina
    Salerno, Gisella V.
    Daniels, Ian R.
    Moran, Brendan J.
    Heald, R. J.
    Thomas, Karen
    DISEASES OF THE COLON & RECTUM, 2010, 53 (03) : 362 - 363
  • [34] Alteration of Clinical Tumor Characteristics Is Associated with Pathological Regression in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy
    Zhanwei Fu
    Zhenghao Cai
    Xuan Zhao
    Hedan Chen
    Zirui He
    Junjun Ma
    Minhua Zheng
    Journal of Gastrointestinal Surgery, 2022, 26 : 2600 - 2605
  • [35] Alteration of Clinical Tumor Characteristics Is Associated with Pathological Regression in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy
    Fu, Zhanwei
    Cai, Zhenghao
    Zhao, Xuan
    Chen, Hedan
    He, Zirui
    Ma, Junjun
    Zheng, Minhua
    JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (12) : 2600 - 2605
  • [36] Influence of CD133~+ expression on patients' survival and resistance of CD133~+ cells to anti-tumor reagents in gastric cancer
    De-Hu Chen
    Rui-Qi Lu
    Xiao-Chun Ni
    Ju-Gang Wu
    Shou-Lian Wang
    Bo-Jian Jiang
    Ji-Wei Yu
    Asian Pacific Journal of Tropical Biomedicine, 2015, (12) : 996 - 1004
  • [37] Impact of tumor regression grade as a major prognostic factor in pathological stage II and III rectal cancer after neoadjuvant chemoradiotherapy
    Kim, J-S.
    Song, C.
    Kang, S-B.
    Lee, H. S.
    Lee, K-W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] CD133 expression associated with poor prognosis in ovarian cancer
    Zhang, Jing
    Guo, Xiaoqing
    Chang, Doo Young
    Rosen, Daniel G.
    Mercado-Uribe, Imelda
    Liu, Jinsong
    MODERN PATHOLOGY, 2012, 25 (03) : 456 - 464
  • [39] Leucine-rich repeat-containing G protein-coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer
    Harada, Yuzo
    Kazama, Shinsuke
    Morikawa, Teppei
    Murono, Koji
    Yasuda, Koji
    Otani, Kensuke
    Nishikawa, Takeshi
    Tanaka, Toshiaki
    Kiyomatsu, Tomomichi
    Kawai, Kazushige
    Hata, Keisuke
    Nozawa, Hiroaki
    Yamaguchi, Hironori
    Ishihara, Soichiro
    Watanabe, Toshiaki
    ONCOLOGY LETTERS, 2017, 14 (06) : 7791 - 7798
  • [40] Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia
    Kazama, Shinsuke
    Kishikawa, Junko
    Tanaka, Toshiaki
    Hata, Keisuke
    Kawai, Kazushige
    Nozawa, Hiroaki
    Ishihara, Soichiro
    IN VIVO, 2019, 33 (04): : 1279 - 1284